MEI Pharma Inc
NASDAQ:MEIP
Intrinsic Value
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. [ Read More ]
The intrinsic value of one MEIP stock under the Base Case scenario is 10.83 USD. Compared to the current market price of 3.23 USD, MEI Pharma Inc is Undervalued by 70%.
Valuation Backtest
MEI Pharma Inc
Run backtest to discover the historical profit from buying and selling MEIP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
MEI Pharma Inc
Current Assets | 66.2m |
Cash & Short-Term Investments | 59.5m |
Other Current Assets | 6.7m |
Non-Current Assets | 12.4m |
PP&E | 12.4m |
Current Liabilities | 8m |
Accounts Payable | 1.4m |
Accrued Liabilities | 6.7m |
Non-Current Liabilities | 11m |
Other Non-Current Liabilities | 11m |
Earnings Waterfall
MEI Pharma Inc
Revenue
|
72.7m
USD
|
Operating Expenses
|
-56.8m
USD
|
Operating Income
|
15.9m
USD
|
Other Expenses
|
4m
USD
|
Net Income
|
19.8m
USD
|
Free Cash Flow Analysis
MEI Pharma Inc
What is Free Cash Flow?
MEIP Profitability Score
Profitability Due Diligence
MEI Pharma Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
MEI Pharma Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
MEIP Solvency Score
Solvency Due Diligence
MEI Pharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
MEI Pharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MEIP Price Targets Summary
MEI Pharma Inc
According to Wall Street analysts, the average 1-year price target for MEIP is 23.46 USD with a low forecast of 7.07 USD and a high forecast of 44.1 USD.
Ownership
MEIP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MEIP Price
MEI Pharma Inc
Average Annual Return | -24.11% |
Standard Deviation of Annual Returns | 46.74% |
Max Drawdown | -96% |
Market Capitalization | 21.5m USD |
Shares Outstanding | 6 662 860 |
Percentage of Shares Shorted | 0.14% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The company went IPO on 2003-12-18. The firm is focused on development and commercialization of novel cancer therapies. The firm's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The firm is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS).
Contact
IPO
Employees
Officers
The intrinsic value of one MEIP stock under the Base Case scenario is 10.83 USD.
Compared to the current market price of 3.23 USD, MEI Pharma Inc is Undervalued by 70%.